Most Recent
NSW Health has hit back at a class action accusing it of failing to pay overtime hours to junior doctors, saying that because they did not submit an overtime claim they were taken to have worked the additional hours “of their own volition”.
Hoping to avoid a lengthy trial like the 89-day hearing in the pelvic mesh class action against Johnson & Johnson's Ethicon, a judge has suggested splitting up a class action hearing over TFS Manufacturing and IVS pelvic mesh products to focus on the question of the devices' safety and efficacy first.
Australian regenerative medicine company Mesoblast faces a shareholder class action over disclosures related to its Remestemcel-L treatment for COVID-19 complications.
A judge has urged the parties in two pelvic mesh class actions against Boston Scientific to come up with a "pragmatic solution" to the competing proceedings filed in the Federal and NSW Supreme courts.
Swiss drug giant Novartis has secured an injunction temporarily blocking drug maker Pharmacor from launching a generic version of the company’s top-selling MS drug Gilenya in Australia.
A Johnson & Johnson unit wants the High Court to review the Full Federal Court's rejection of its challenge to a landmark class action ruling that found the company's pelvic mesh implants were defective and that it failed to adequately warn about their risks.
Johnson & Johnson's Ethicon unit is facing a second class action over its allegedly defective pelvic mesh products, following a landmark ruling that found the drug company did not adequately warn about the devices' risks.
A court has ordered Avant Insurance to supply certain documents to a plastic surgeon seeking coverage for legal costs of defending a class action against The Cosmetic Institute over allegedly "incompetent" breast augmentation surgery.
A patent battle between Juno Pharmaceuticals and Bristol-Myers Squibb over the blockbuster drug Revlimid has seen both sides suffer early losses, with a judge dismissing strike out and summary dismissal applications by the drug makers.
The University of New South Wales has been taken to court by a former tenured professor who alleges she was terminated after making complaints about discrimination against female academics, bullying and misuse of her intellectual property.